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Preface to the 11th Edition
Eight years after the publication of the 10th edition in
2007, the 11th edition of the Japanese Classification of
Esophageal Cancer has now been published. During this
period, supplements to the 10th edition involving the
revision of ‘‘disease typing’’ and terminology were pub-
lished in 2008; in addition, following the adoption of cri-
teria for the diagnosis of lesions located at the
gastroesophageal junction that was made in cooperation
with the Japanese Gastric Cancer Association, a 7-page
leaflet was attached to this Classification in September
2013. The present revision was aimed at ensuring consis-
tency with other general rules for surgical and pathological
studies on cancer as far as possible, reflecting the latest
advances in the diagnosis and treatment of esophageal
cancer in Japan and providing a set of rules that are easier
to use and that facilitate improvements in treatment out-
comes. During this revision, we attempted to secure con-
sistency with the UICC’s TNM classification as far as
possible. However, this attempt was skipped for the N
classification, since the current edition (7th) of the TNM
classification does not reflect the nationwide registry data
of the Japan Esophageal Society and because the rules for
studies on supraclavicular lymph nodes are completely
different between our classification and the N classifica-
tion. This is a significant issue that will need to be
addressed in the next revision.
Using nationwide registry data, the effects of regional
lymph node excision were reviewed from the viewpoints of
lymph node metastasis and the survival rate. As a result,
the lymph node groupings were modified (T4 was subdi-
vided into two subtypes, similar to the TNM classification).
Following recent advances and the spread of endoscopic
treatment, findings from endoscopic treatment have now
been incorporated into the description methods, and the
exclusion of cancer from intraepithelial neoplasms has
been clarified. This revised edition has been prepared as a
result of numerous discussions among committee mem-
bers. Although there are still some questions to be dis-
cussed, we wish to take this opportunity to thank the
considerable efforts made by the individual committee
members.
October, 2015
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General principles of this edition
1. Following the spread of endoscopic treatment, find-
ings from endoscopic treatment (e) have been added to the
methods used to describe findings.
2. The criteria for the diagnosis of lesions located at the
gastroesophageal junction, which have been jointly adop-
ted by the Japanese Gastric Cancer Association, have been
added to the main text.
3. Regarding the depth of tumor invasion, the subgroup
T1b- has been added to the subgroup T1b, similar to that
for T1a, and the subgroup T4 has been further subdivided
into T4a and T4b so as to be consistent with the UICC’s
TNM classification.
4. Regarding lymph nodes, No. 112ao has been divided
into the esophageal side and the dorsal side. Furthermore,
to secure consistency with the general rules for surgical and
pathological studies on gastric cancer, No. 3 has been
divided into No. 3a and No. 3b.
5. Regarding lymph node grouping, modifications have
been made to Ut (Group 3 only), Mt/Lt (Groups 1, 2, 3),
and Ae (Groups 2, 3). In accordance with the revision of
the criteria for the diagnosis of lesions located at the gas-
troesophageal junction, the same lymph node classification
as that used for Ae will now be applied to cancer of the
gastroesophageal junction.
6. Regarding the stage of cancer, T1aN1 is now classi-
fied as Stage II, as is the case with T1bN1. T4a up to N3 is
now classified as Stage III. T4b, beginning with N0, is now
classified as Stage IVa.
7. Regarding the extent of residual cancer, classification
into R1 based on macroscopic findings is now avoided,
consistent with the general rules for surgical and patho-
logical studies on colorectal cancer.
8. Regarding histopathological findings, it has now
been made clear that carcinoma in situ is not to be
included among neoplasms within the squamous epithe-
lium. The extent of differentiation of both squamous cell
carcinoma and adenocarcinoma is now described as ‘‘well
differentiated’’ or a similar expression, omitting any
description of type. Endocrine cell neoplasm is now
called neuroendocrine tumor, consistent with the WHO
classification. Also, concerning extralymph node metas-
tasis, the expression ‘‘tumor nodule’’ has been adopted,
consistent with the general rules for surgical and patho-
logical studies on colorectal cancer. Vascular invasion in
specimens collected during endoscopic treatment is now
rated as (-) or (?), consistent with the method used for
gastric cancer.
9. The TNM classification adopted for the revised
classification has been switched to the Japanese translation
of the TNM classification, 7th edition.
10. Regarding the number of lymph node metastases, the
conventional rule for the correction of grouping according
to the number of metastases was too complex and was not
used frequently. This rule has been deleted from the
revised edition.
11. The endoscope pictures have been replaced with
clearer ones.
12. Regarding the extents and borders of the lymph
nodes, not only schematic figures, but also actual CT
images have been provided to simplify understanding,
accompanied by the presentation of features that will also
be useful for radiotherapy.





AI Invasion to the adjacent structures







CTV Clinical target volume
Cur Curativity
D Lymph node dissection
DFS Disease-free survival
DM Distal margin
DMM Deep muscularis mucosae
E Esophagus
EG Tumor located in the esophageal side
EGJ Esophagogastric junction
EMR Endoscopic mucosal resection
EP Epithelium [p.41, 74]
ER Endoscopic resection
ESD Endoscopic submucosal dissection
EVG Elastica van Gieson staining
f Final findings
G Stomach
GE Tumor located in the gastric side





INF Infiltrative growth pattern
IR/SD Incomplete response/stable disease
IT Immunotherapy
LN Lymph node
LPM Lamina propria mucosae
LSBE Long segment Barrett esophagus
Laser Laser therapy
Lt Lower thoracic esophagus
Ly Lymphatic invasion
ly/v Lymphatic invasion or venous invasion
M Distant organ metastasis
MCT Microwave coagulation therapy
MFH Malignant fibrous histiocytoma
MM Muscularis mucosae
MP Muscularis propria
MST Median survival time
Mt Middle thoracic esophagus
















S Superior margin of the sternum




SMM Superficial muscularis mucosae
SSBE Short segment Barrett esophagus
T Depth of tumor invasion
Te Thoracic esophagus
Tis Carcinoma in situ
TT Thermotherapy
TTF Time to treatment failure
TTP Time to progression
Ut Upper thoracic esophagus
v Venous invasion
VB Victoria blue staining
VM Vertical margin [p. 39]
X Cannot be assessed [p. 2]














Number of the lymph nodes
a: 1–3, b: 4–7, c: ]8




1. Purpose, object, and methods of descriptions
1.1. Purpose
‘‘The Guidelines for the Clinical and Pathologic Studies on
Carcinoma of the Esophagus’’ was originally published in
1969 by the Japanese Society for Esophageal Diseases.
Since then, the Society has changed its name in 2003 to
become the Japan Esophageal Society, and has published
the ‘‘Japanese Classification of Esophageal Cancer’’ in
Japanese with some revisions to keep up to date with
treatment results and to provide a standard nomenclature.
To promote the international use of the Guidelines and the
Classification, the Society is publishing this handbook in
English entitled ‘‘The Japanese Classification of Esopha-
geal Cancer’’.
1.2. Object
The term esophageal cancer in the Japanese Classification
refers to cancer originating in the esophagus, and cancer
metastatic to the esophagus is excluded. All primary
malignant tumors in the esophagus should be described
according to the Japanese Classification.
1.3. Methods of descriptions
1.3.1. Principles of descriptions and abbreviations
Findings are recorded using upper-case letters T (depth
of tumor invasion), N (lymph node metastasis) and M
(distant organ metastasis). The extent of each finding is
expressed by Arabic numerals following each upper-
case letter. ‘‘X’’ is used in unknown cases. Five cate-
gories of findings, namely Clinical, Endoscopic treat-
ment, Surgical, Pathological, and Final findings, are
identified using the lower case ‘‘c’’, ‘‘e’’, ‘‘s’’, ‘‘p’’, and
‘‘f’’, respectively, before each upper-case letter. The
‘‘f’’ of Final findings can be omitted (Tables 1-1, 1-2).
Checklists for descriptions of the Japanese Classifica-
tion of Esophageal Cancer are shown in the following
tables (Tables 1-3, 1-4).
The order of clinicopathological description is:
Tumor location (in addition to describing the distance from
the incisor), circumferential extent, tumor length, macro-
scopic tumor type, histological type (when identified),
depth of tumor invasion, lymph node metastasis, distant
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Table 1-2 Description methods
Clinical findings Endoscopic treatment findings Surgical findings Pathological findings Final findings
Depth of tumor invasion cT eT sT pT (f) T
Lymph node metastasis cN – sN pN (f) N
Distant organ metastasis cM – sM pM (f) M
Intramural metastasis cIM eIM sIM pIM (f) IM
Stage cStage eStage sStage pStage (f) Stage
Proximal margin – – sPM pPM (f) PM
Distal margin – – sDM pDM (f) DM
Radial margin – – sRM pRM (f) RM
Horizontal margin (EMR/ESD) – eHM sHM pHM (f) HM
Vertical margin (EMR/ESD) – eVM sVM pVM (f) VM
–
Residual tumor – eR sR pR (f) R
Curativity – eCur sCur pCur (f) Cur
Findings modified by treatment methods other than surgery are abbreviated as follows: RT radiotherapy, CT chemotherapy, CRT chemora-
diotherapy, EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, laser laser therapy, PDT photodynamic therapy
Table 1-3 Checklist for descriptions of the Japanese Classification of Esophageal Cancer (surgically treated cases)
Tumor location: Ce, Ut, Mt, Lt, Ae
Size: maximum length (mm) and orthogonally oriented maximum width (mm)
Macroscopic tumor type:
Type 0, Type 1, Type 2, Type 3, Type 4, Type 5, Combined type, Others
Subclassification for superficial cancers: 0-I(0-Ip, 0-Is), 0-II(0-IIa, 0-IIb, 0-IIc), 0-III
Histological type: squamous cell carcinoma, basaloid (-squamous) carcinoma, carcinosarcoma, adenocarcinoma, Barrett’s adenocarcinoma,
adenosquamous carcinoma, mucoepidermoid carcinoma, adenoid cystic carcinoma, neuroendocrine cell tumor, undifferentiated carcinoma,
other carcinomas, non-epithelial malignant tumors, GIST, malignant melanoma
Depth of tumor invasion: pTX, pT0, pT1a (EP, LPM, MM), pT1b (SM1, SM2, SM3), pT2, pT3, pT4
Pattern of infiltration: INFa, INFb, INFc
Lymphatic invasion: ly0, ly1, ly2, ly3
Venous invasion: v0, v1, v2, v3
Intramural metastasis: pIMX, pIM0, pIM1
Involvement of resection margins
Proximal margin: pPMX, pPM0, pPM1
Distal margin: pDMX, pDM0, pDM1
Radial margin: pRMX, pRM0, pRM1
Multiple primary cancers: absent, present (number)
Lymph node metastasis: pNX, pN0, pN1, pN2, pN3, pN4
Number of positive nodes (No. of lymph node stations with positive nodes)
Distant metastasis: M0, M1
Residual tumor: pRX, pR0, pR1, pR2
Histological curativity: pCurA, pCurB, pCurC
Distant organ metastasis: MX, M0, M1; Intramural gastric metastasis: pIM1-St
Therapeutic efficacy: No data, Grade 0, Grade 1a, Grade 1b, Grade 2, Grade 3
Curativity: Cur A, Cur B, Cur C
Esophagus (2017) 14:1–36 11
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e.g.: Mt (31–36 cm), 1/2 of circumference and on anterior
wall, 5 cm, Type 2, moderately differentiated squamous
cell carcinoma, pT3, pN2, sM0, fStage III.
The order of pathological description is:
Tumor location, tumor length, macroscopic tumor type,
histological type, depth of tumor invasion, pattern of
infiltration, lymphatic invasion, venous invasion, intramu-
ral metastasis, involvement of the resection margins
(proximal margin, distal margin, and radial margin), mul-
tiple primary cancers, effects of radiation and/or anticancer
chemotherapy, lymph node metastasis, distant organ
metastasis, and stage.
e.g.: Mt, 5 cm, Type 2, moderately differentiated squamous
cell carcinoma, pT3, INFa, ly1, v1, IM0, pPM0, pDM0,
pRM0, multiple primary carcinomas (present, two lesions),
CRT-grade 2, pN1 (2/30), sM0, fStage III.
2. Clinical aspects
2.1. Description of primary tumor
2.1.1. Number of primary tumors, size and
circumferential location
Maximum length (mm) and orthogonally oriented maxi-
mum width (mm), center of circumferential extent, and
circumferential ratio of the tumor to the entire esophagus
should be described. In addition, the methods used for
diagnosis, such as barium X-ray, endoscopy and EUS,
should be recorded.
2.1.2. Tumor location
2.1.2.1. Anatomical definition of the esophagus
The esophagus is defined anatomically from the esophageal
orifice to the esophagogastric junction. The esophageal
orifice is at the lower margin of the cricoid cartilage. The
identification of the esophagogastric junction (EGJ) will be
described later.
2.1.2.2. Anatomical regions (subsites) of the esophagus
The esophagus lies between the hypopharynx and stomach,
and can be anatomically divided into the following por-
tions; cervical esophagus (Ce), thoracic esophagus (Te) and
abdominal esophagus (Ae). The zone of the esophagogas-
tric junction is divided into the esophageal side (E) and
gastric side (G) (Fig. 1-1).Note
Cervical esophagus (Ce): This extends from the esophageal
orifice to the sternal notch.
Thoracic esophagus (Te): From the sternal notch to the
superior margin of the esophageal hiatus.
Upper thoracic esophagus (Ut): From the sternal notch
to the tracheal bifurcation.
Middle thoracic esophagus (Mt): The proximal half of
the two equal portions between the tracheal bifurcation and
the esophagogastric junction.
Lower thoracic esophagus (Lt): The thoracic part of the
distal half of the two equal portions between the tracheal
bifurcation and the esophagogastric junction.
Abdominal esophagus (Ae): The abdominal part of the
distal half of the two equal portions between the tracheal
bifurcation and the esophagogastric junction (from the
Table 1-4 Checklist for descriptions of the Japanese Classification of
Esophageal Cancer (endoscopically treated cases)
Macroscopic findings
Tumor location: Ce, Ut, Mt, Lt, Ae
Macroscopic tumor type: Type 0-I, Type 0-IIa, Type 0-IIb, Type
0-IIc, Type 0-III, combined type, others
Size of specimen: length (mm), width (mm)
Size of tumor: length (mm), width (mm)
Resection: en bloc resection, piecemeal resection
Piecemeal resection: number of specimens
Horizontal margin: HMX, HM0, HM1
Vertical margin: VMX, VM0, VM1
Multiple lesions: present, absent
Histological findings
Histological type: squamous cell carcinoma, basaloid (-squamous)
carcinoma, carcinosarcoma, adenocarcinoma, Barrett’s
adenocarcinoma, adenosquamous carcinoma, mucoepidermoid
carcinoma, adenoid cystic carcinoma, neuroendocrine cell
tumor, undifferentiated carcinoma, other carcinomas, non-
epithelial malignant tumors, GIST, malignant melanoma
Depth of tumor invasion: pTX, pT0, pT1a (EP, LPM, MM), T1b
(SM1, SM2, SM3)
Pattern of infiltration: INFa, INFb, INFc
Lymphatic invasion: ly (-), ly (?)
Venous invasion: v (-), v (?)
Size of tumor: length (mm) 9 width (mm)
Horizontal margin: pHMX, pHM0, pHM1
Vertical margin: pVMX, pVM0, pVM1
Residual tumor: pRX, pR0, pR1, pR2
Curativity: pCur A, pCur B, pCur C
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superior margin of the esophageal hiatus to the esopha-
gogastric junction).
Note: The zone of the esophagogastric junction is
defined as the region between 2 cm in esophagus and
2 cm in the stomach from the esophagogastric junction.
The abdominal esophagus is included in this zone.
2.1.2.3. Principles of description of tumor location
Describe the tumor location identified by examinations
according to the following order of priority: barium X-ray,
CT, and endoscopic measurements. Include the distance
from the incisor in addition to the tumor location. When the
tumor location is uncertain because examinations other
than endoscopy have yet to be performed, describe only the
distance from the incisor.
When the tumor extends continuously in more than one
portion of the esophagus, the main tumor location is that
with the deepest tumor invasion. If it is difficult to deter-
mine the site of deepest tumor invasion, the portion at the
central point of the tumor can be recorded as the main
tumor location.
In the case of multiple primary lesions, the locations of the
lesions are described in the order of depth of tumor inva-
sion. The deepest lesion is described first. If it is difficult to
determine the order of the depth, the description order
depends on the size of the area occupied by the lesion. The
largest lesion is described first.
e.g.: MtLt, LtAeG.
2.1.3. Macroscopic tumor type
2.1.3.1. Principles of tumor type classification
The tumor type classification is based on the macroscopic
findings. Radiological and endoscopic classifications are
based on the macroscopic classification.
Tumors in which invasion is macroscopically diagnosed
to be limited to within the submucosa are classified as
superficial type, while tumors in which invasion is
diagnosed to extend to the muscularis propria or
beyond are classified as advanced type. The superficial
type has the prefix ‘0’ and is classified into 0-I, 0-II or
0-III. The advanced type is divided into 4 categories: 1,
2, 3, or 4. When a tumor cannot be classified into any
of the 5 (0–4) categories or their combinations, it is
classified as 5.
2.1.3.2. Macroscopic classification (Fig. 1-2)Note 1
Type 0 Superficial type
Type 1 Protruding type
Type 2 Ulcerative and localized type
Type 3 Ulcerative and infiltrative type
Type 4 Diffusely infiltrative type
Type 5 Unclassifiable type
Type 5a Unclassifiable type without treatment
Type 5b Unclassifiable type after treatmentNotes 1, 2
Note 1: The macroscopic tumor type before chemother-
apy and/or radiotherapy is described. Previous treatment
is indicated. Cases with minor changes following
treatment and which fit the macroscopic tumor
type(s) are classified as type 1–4 and cases of major
changes are designated as unclassifiable type.
Note 2: Any former treatment(s) is mentioned before the
macroscopic tumor type. e.g.: CT-3, CRT-5b, EMR-0-IIc
Fig. 1-1 Tumor location. O esophageal orifice, S superior margin of
the sternum, B tracheal bifurcation, D diaphragm, EGJ esophagogas-
tric junction, H esophageal hiatus
Fig. 1-2 Macroscopic classification (Type 0–4)
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2.1.3.3. Subclassification of superficial type (type 0)
Type 0-I Superficial and protruding type
Type 0-Ip Pedunculated type
Type 0-Is Sessile (broad based) type
Type 0-II Superficial and flat type
Type 0-IIa Slightly elevated type
Type 0-IIb Flat type
Type 0-IIc Slightly depressed type
Type 0-III Superficial and excavated type
Other notations
Note 1: Combined type: When multiple macroscopic
tumor types are mixed in one lesion, it is called a
combined type. The wider type is described first and
types are connected with ?. Double quotation marks
(‘‘’’) are placed around the macroscopic tumor type that
has the deepest tumor invasion. In this case, the main
macroscopic tumor type is the deepest one. However,
when an advanced type is mixed with a superficial type,
the advanced type is described first and double quotation
marks are unnecessary.
e.g.: 0-IIc?‘‘0-Is’’, 3?0-IIc.
Note 2: Superficial spreading type: superficial type 0-II
in which the maximal length of the tumor extends 5 cm
or more longitudinally. It may be noted additionally in
the macroscopic tumor type.
[Reference]
Japanese Society for Esophageal Diseases. Guidelines for the Clinical and
Pathologic Studies on Carcinoma of the Esophagus (in Japanese). 8th ed.
Kanehara Shuppan, Tokyo, 1992; 34.
2.1.4. Depth of tumor invasion (T)
TX Depth of tumor invasion cannot be assessed
T0 No evidence of primary tumor
T1a Tumor invades mucosaNote 1(Fig 1-3)
T1a-EP Carcinoma in situ (Tis)
T1a-LPM Tumor invades lamina propria mucosae
(LPM)
T1a-MM Tumor invades muscularis mucosae (MM)
T1b Tumor invades submucosa (SM)Notes 2, 3, 4
T1b-SM1 Tumor invades the upper third of the
submucosal layer
T1b-SM2 Tumor invades the middle third of the
submucosal layer
T1b-SM3 Tumor invades the lower third of the
submucosal layer
T2 Tumor invades muscularis propria (MP)
T3 Tumor invades adventitia (AD)
T4 Tumor invades adjacent structures (AI)Notes 5, 7
T4a Pleura, pericardium, diaphragm, lung, tho-
racic duct, azygos vein, nerve.
T4b Aorta (great artery), trachea, bronchus, pul-
monary vein, pulmonary artery, vertebral body.
Note 1: Early esophageal cancer: T1a can be designated
as early cancer of the esophagus regardless of the
presence or absence of lymph node or distant organ
metastasis. e.g.: early esophageal cancer: T1aNxMx.
Note 2: Superficial esophageal cancer: T1a and T1b are
designated as superficial cancer regardless of lymph
node or distant organ metastasis.
e.g.: superficial esophageal cancer: T1NxMx
Note 3: Formerly used subclassification of superficial
type generally corresponds to the following.
M1: T1a-EP, M2: T1a-LPM, M3: T1a-MM, SM1: T1b-
SM1, SM 2: T1b-SM2, SM 3: T1b-SM3
Note 4: In endoscopically resected specimens, a tumor
invading the submucosa to a depth of 200 lm or less
from the lamina muscularis mucosae is classified as T1b-
SM1, while a tumor extending more than 200 lm is
classified as T1b-SM2, since the distance of the submu-
cosal layer is unknown.
Note 5: Invaded organs such as the pericardium, aorta,
vena cava, trachea, lung, diaphragm, thoracic duct,
recurrent laryngeal nerve, azygos vein should be
recorded.
e.g.: T4a (lung).
Note 6: When a metastatic lymph node additionally
invades a surrounding organ other than the esophagus, it
should be classified as T4 and recorded as ‘‘T4
(metastatic node number-invaded organ)’’.
e.g.: T4b (No.112aoA-Aorta).
Fig. 1-3 Subclassification for superficial cancer (modified from the
guidelines for esophageal cancer treatment)
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2.2. Metastatic lesions from esophageal cancer
2.2.1. Lymph node metastasis
2.2.1.1. Naming and numbers of lymph node stations
The names and numbers of lymph nodes are defined as
shown in Table 1-5 and Fig. 1-4. The stations of cervical
and thoracic lymph nodes are shown in Figs. 1-5, 1-6 and
1-7. The names and numbers of abdominal lymph node
stations are defined in the Japanese Classification of Gas-
tric Carcinoma (Table 1-5).
Note: The number of lymph node stations should be
recorded using ‘‘No.’’ plus a number.
e.g.: No.106recR.
[Reference]
Japanese Gastric Cancer Association. Japanese Classification of Gastric
Carcinoma. 14th ed. Kanehara Shuppan, Tokyo, 2010.
Fig. 1-4 Station numbers of regional lymph nodes
Fig. 1-5 Superficial cervical lymph nodes
Fig. 1-6 Deep cervical lymph nodes
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Fig. 1-7 Tracheobronchial lymph nodes (right view of the trachea)
(posterior view of the trachea)
Table 1-5 Numbers and naming of regional lymph nodes
(1) Cervical lymph nodes* (Figs. 1-4, 1-5, 1-6)
No. 100 Superficial lymph nodes of the neck
No. 100spf Superficial cervical lymph nodes
No. 100sm Submandibular lymph nodes
No. 100tr Cervical pretracheal lymph nodes
No. 100ac Accessory nerve lymph nodes
No. 101 Cervical paraesophageal lymph nodes
No. 102 Deep cervical lymph nodes
No. 102up Upper deep cervical lymph nodes
No. 102mid Middle deep cervical lymph nodes
No. 103 Peripharyngeal lymph nodes
No. 104 Supraclavicular lymph nodes
(2) Thoracic lymph nodes
(Figs. 1-4, 1-7)
No. 105 Upper thoracic paraesophageal lymph nodes
No. 106 Thoracic paratracheal lymph nodes
No. 106rec Recurrent nerve lymph nodes
No. 106recL Left recurrent nerve lymph nodes
No. 106recR Right recurrent nerve lymph nodes
No. 106pre Pretracheal lymph nodes
No. 106tb Tracheobronchial lymph nodes
No. 106tbL Left tracheobronchial lymph nodes
No. 106tbR Right tracheobronchial lymph nodes
No. 107 Subcarinal lymph nodes
No. 108 Middle thoracic paraesophageal lymph nodes
No. 109 Main bronchus lymph nodes
No. 109L Left main bronchus lymph nodes
No. 109R Right main bronchus lymph nodes
No. 110 Lower thoracic paraesophageal lymph nodes
No. 111 Supradiaphragmatic lymph nodes
No. 112 Posterior mediastinal lymph nodes
No. 112aoA Anterior thoracic paraaortic lymph nodes
No. 112aoP Posterior thoracic paraaortic lymph nodes
No. 112pul Pulmonary ligament lymph nodes
No. 113 Ligamentum arteriosum lymph nodes (Botallo
lymph nodes)
No. 114 Anterior mediastinal lymph nodes
(3) Abdominal lymph nodes (Fig. 1-4)
No. 1 Right paracardial lymph nodes
No. 2 Left paracardial lymph nodes
No. 3a Lesser curvature Lymph nodes along the branches
of the left gastric artery
No. 3b Lesser curvature Lymph nodes along the 2nd
branches and distal part of the right gastric artery
No. 4 Lymph nodes along the greater curvature
No. 4sa Lymph nodes along the short gastric vessels
No. 4sb Lymph nodes along the left gastroepiploic artery
No. 4d Lymph nodes along the right gastroepiploic artery
No. 5 Suprapyloric lymph nodes
No. 6 Infrapyloric lymph nodes
No. 7 Lymph nodes along the left gastric artery
No. 8a Lymph nodes along the common hepatic artery
(anterosuperior group)
No. 8p Lymph nodes along the common hepatic artery
(Posterior group)
No. 9 Lymph nodes along the celiac artery
No. 10 Lymph nodes at the splenic hilum
No. 11 Lymph nodes along the splenic artery
No. 11p Lymph nodes along the proximal splenic artery
No. 11d Lymph nodes along the distal splenic artery
No. 12 Lymph nodes in the hepatoduodenal ligament
No. 13 Lymph nodes on the posterior surface of the
pancreatic head
No. 14 Lymph nodes along the superior mesenteric vessels
No. 14A Lymph nodes along the superior mesenteric artery
No. 14V Lymph nodes along the superior mesenteric vein
No. 15 Lymph nodes along the middle colic artery
No. 16 Lymph nodes around the abdominal aorta
No. 16a1 Lymph nodes in the aortic hiatus
No. 16a2 Lymph nodes around the abdominal aorta (from the
upper margin of the celiac trunk to the lower
margin of the left renal vein)
No. 16b1 Lymph nodes around the abdominal aorta (from the
lower margin of the left renal vein to the upper
margin of the inferior mesenteric artery)
No. 16b2 Lymph nodes around the abdominal aorta (from the
upper margin of the inferior mesenteric artery to
the aortic bifurcation)
No. 17 Lymph nodes on the anterior surface of the
pancreatic head
No. 18 Lymph nodes along the inferior margin of the
pancreas
No. 19 Infradiaphragmatic lymph nodes
No. 20 Lymph nodes in the esophageal hiatus of the
diaphragm
The left side (L) and the right side (R) should be distinguished for
101, 102, 104, 106rec, 106tb, 109, and 112pul
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2.2.1.2. Lymph node groups
Lymph node groups are defined according to the location
of the tumor as shown in Table 1-6, Figs. 1-8, 1-9, 1-10, 1-
11 and 1-12.
Note: In deciding the lymph node group of multiple
esophageal cancers and widely extending esophageal
cancer, the location of the deepest tumor invasion takes
precedence in documentation.
2.2.1.3. Grading of lymph node metastasis (N)
NX Lymph node metastasis cannot be assessed
N0 No lymph node metastasis
N1 Metastasis involving only Group 1 lymph nodes
N2 Metastasis to Group 2 lymph nodes, regardless of
involvement of Group 1 lymph nodes
N3 Metastasis to Group 3 lymph nodes, regardless of
involvement of Group 1 or 2 lymph nodes
N4 Metastasis to distant (Group 4) lymph nodes,
regardless of whether any other group(s) of regional
lymph nodes are involved or not
Table 1-6 Lymph node groups according to the location of the tumor
Tumor location Group 1 (N1) Group 2 (N2) Group 3 (N3)
Cervical Ce 101, 106reca 102, 104, 105a 100
Upper thoracic Ut 101, 105, 106rec 104, 106tbL, 107, 108, 109 102mid, 106pre, 106tbR, 110, 112aoA, 112pul,
1, 2, 3a, 7, 20
Middle thoracic Mt 106rec, 108, 1, 2, 3a 101, 104, 105, 107, 109, 110, 112aoA,
112pul, 7, 9, 20
106tbL
Lower thoracic Lt 110, 1, 2, 3a, 7, 20 101, 106rec, 107, 108, 109, 112aoA, 112pul,
9
104, 105, 106tbL, 111, 8a, 11p
Abdominal Ae 110, 1, 2, 3a, 7, 20 111, 112aoA, 112pul, 8a, 9, 11p, 19 106rec, 107, 108, 109, 11d
Nodes other than N1 through N3 are expressed as N4
a Limited to the area which can be dissected from the cervical incision
Fig. 1-8 Lymph node groups for tumors located in Ce Fig. 1-9 Lymph node groups of tumors located in Ut
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Note: Extralymph node metastasis (tumor nodule) is
included within N.
2.2.2. Distant organ metastasis (M)
MX Distant organ metastasis cannot be assessed
M0 No distant organ metastasis
M1 Distant organ metastasis
Note 1: Organs with metastasis should be recorded in
parentheses.
e.g.: M1 (lung), M1 (liver, stomach).
Note 2: Pleural, peritoneal, and pericardial dissemination
should be recorded as M1.
2.3. Stage (Table 1-7)
The stage should be recorded based on the following TNM
stage classification.
e.g.: T2N2M0, Stage III.
2.4. Multiple primary cancers
Multiple primary cancers of the esophagus:
The term ‘‘multiple primary cancers of the esophagus’’ is
used to refer to the presence of two or more primary eso-
phageal cancers.
Fig. 1-10 Lymph node groups for tumors located in Mt
Fig. 1-11 Lymph node groups for tumors located in Lt
Fig. 1-12 Lymph node groups for tumors located in Ae (EG)
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Note: Descriptions of the locations of multiple primary
cancers of the esophagus should be made according to
the order of the depth of tumor invasion (deeper to
shallower), inserting ‘‘/’’ between the abbreviations for
the location of each lesion; the total number of lesions
should also be recorded in parentheses.
e.g.: MtUt/Lt/Lt (3 lesions).
Multi-organ primary cancers including the esophagus:
The term ‘‘multi-organ primary cancers including the
esophagus’’ is used to refer to the presence of one or more
primary malignant diseases other than esophageal cancer in
a patient with primary esophageal cancer.
Multiple primary cancers including the esophagus:
The term ‘‘multiple primary cancers including the esoph-
agus’’ indicates the concept combining both ‘‘multiple
primary cancers of the esophagus’’ and ‘‘multi-organ pri-
mary cancers including the esophagus’’.
Note 1: In cases with multi-organ primary cancers
including the esophagus, organs other than the esopha-
gus should be specified in parentheses.
Note 2: Whether the multiplicity is synchronous or
metachronous should be recorded.
e.g.: Multi-organ primary cancers: stomach (synchronous).
3. Surgical aspects
3.1. Handling of the resected specimen
The resected esophagus should be cut and opened along the
longitudinal line on the side opposite to the lesion. The
opened esophagus should be gently stretched longitudinally
and fixed so that the length of the specimen becomes
similar to its size in vivo. The specimen should be treated
with iodine solution after fixation in order to accurately
describe the macroscopic findings. This is particularly
important in superficial carcinoma. Photographic recording
is recommended for both fresh and fixed specimens.
3.2. Description of surgical findings and macroscopic
findings of primary tumor
Operative findings should be identified in the record put-
ting ‘‘s’’ in front of each factor.
e.g.: sT2, sStageII.
3.2.1. Tumor size (Fig. 1-13)
The greatest longitudinal dimension in millimeters and the
greatest transverse (at 90 to the longitudinal tumor axis)
dimension in millimeters: a 9 b (mm)
Table 1-7 Stage
Metastasis   
Depth                
of tumor invasion
N0 N1 N2 N3 N4 M1
T0, T1a 0 II II III IVa IVb
T1b I II II III IVa IVb
T2 II II III III IVa IVb
T3 II III III III IVa IVb
T4a III III III III IVa IVb
T4b IVa IVa IVa IVa IVa IVb
T4a pleura, pericardium, diaphragm, lung, thoracic duct, azygos vein, nerve
T4b aorta (large vessel), trachea, bronchus, pulmonary vein, pulmonary artery, vertebra
Fig. 13 Tumor size and the distance from resection margin to tumor.
a Greatest longitudinal dimension (mm). b Greatest transverse
dimension (mm)
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3.2.2. Distance from surgical margin to the tumor
(Fig. 1-13)
Proximal (oral) margin (PM) (mm)
Distal (anal) margin (DM) (mm)
3.2.3. Macroscopic tumor type
The macroscopic appearance of tumors before and after fix-
ation can be different. Under such circumstances, the
macroscopic tumor type should be described according to pre-
fixation observations, and the pathological tumor type should
be described based on the post-fixation findings. Pathological
tumor types can be classified referring to the cross-sectional
observation. Macroscopic tumor types should be determined
regardless of microscopic depth of tumor invasion.
Note: The presence of preoperative chemotherapy and
radiotherapy should be recorded with the macroscopic
tumor type.
3.2.4. Surgical margin
3.2.4.1. PM: Proximal (oral) margin
PMX Proximal margin cannot be assessed
PM0 No evidence of tumor invasion
PM1 Tumor invasion
3.2.4.2. DM: Distal (anal) margin
DMX Distal margin cannot be assessed
DM0 No evidence of tumor invasion
DM1 Tumor invasion
Note: The distance from the resection margin to tumor
should be recorded in millimeters for PM0 and DM0
specimens.
3.2.5. RM: Radial margin
RMX Radial margin cannot be assessed
RM0 No evidence of tumor invasion
RM1 Tumor invasion
Note: The radial margin is the surgical margin in the
radial direction, i.e., the outer surface of the surgical
dissection plane.
3.3. Intramural metastasis and multiple cancers in the
esophagus
3.3.1. IM: Intramural metastasis
Metastatic lesions in the esophageal, pharyngeal, or gastric
wall macroscopically (clearly) separate from the primary
tumor should be recorded as IM, and the number of such
lesions should be described.
IMX Intramural metastasis cannot be assessed
IM0 No intramural metastasis
IM1 Intramural metastasis
Note: IM in the gastric wall should be recorded as ‘‘IM1-
St’’. It is classified as organ metastasis (M1).
3.3.2. Multiple cancers of the esophagus
Multiple cancers are two or more primary cancer lesions
separate from each other. Multiple cancers and IM should
be clearly differentiated in the description.
3.4. Lymph nodes
3.4.1. Preparation of resected lymph nodes for pathologi-
cal examination
Surgically dissected lymph nodes are classified according
to the definition of regional lymph nodes, given individual
names or numbers and sent to pathologists. The lymph
nodes dissected en bloc with the esophagus should be
isolated from the specimen before fixation.
3.4.2. Grading of lymph node metastasis (N)
The surgical diagnosis of the grading of lymph node
metastasis (sN) should be made comprehensively with
intraoperative findings of macroscopic observation, imag-
ing examinations, immediate pathological diagnosis with
frozen section, and macroscopic findings obtained during
postoperative preparation.
3.4.3. Lymph node dissection (D)
3.4.3.1. Field of lymph node dissection
Three-field
dissection
Dissection of cervical, thoracic and
abdominal lymph nodes through




Dissection of thoracic and abdominal
lymph nodes through thoracic and
abdominal approaches,
respectively.Dissection of cervical and
abdominal lymph nodes through cervical
and abdominal approaches,
respectively.Dissection of cervical and
thoracic lymph nodes through cervical
and thoracic approaches, respectively.




Dissection of a single field of cervical,
thoracic and abdominal lymph nodes
through cervical, thoracic or abdominal
approaches, respectively.
Note: The term ‘‘three-field dissection’’ should not be
applied when only the cervical paraesophageal nodes
(101R, 101 L) are dissected in the neck.
3.4.3.2. Extent of lymph node dissection (D)
DX Extent of lymph node dissection cannot be assessed.
D0 No or incomplete dissection of Group-1 lymph
nodes.
D1 Complete dissection of Group-1 lymph nodes, but no
or incomplete dissection of Group-2 lymph nodes.
D2 Complete dissection of Group-1 and Group-2 lymph
nodes, but no or incomplete dissection of Group-3
lymph nodes.
D3 Complete dissection of Group-1, Group-2 and
Group-3 lymph nodes
3.5. Distant organ metastasis (M)
Surgical findings of distant organ metastasis (sM) should
be determined through comprehensive consideration of
operative macroscopic findings, intraoperative imaging
examinations such as intraoperative ultrasound examina-
tion, macroscopic observation of resected specimen, and
intraoperative immediate pathological diagnosis with fro-
zen section. Whether the distant organ metastasis was
resected or not should be recorded.
3.6. Residual tumor (R)Note 1 (Fig. 1-14)
RX Presence of residual tumor cannot be assessed.
R0 No residual tumor.
R1 Microscopic residual tumorNote 2
R2 Macroscopic residual tumorNote 3
Note 1: The postoperative state of both primary tumor
and metastatic lesions should be evaluated.
Note 2: This refers to the presence of a tumor on the
surgical margin of the resected specimen that was
identified upon microscopic examination.
Note 3: This refers to a macroscopically obvious residual
tumor.
3.7. Curativity (Cur) (Table 1-8)
Cur A Complete removal of the tumor is strongly
believed.
sStage 0–III, and sR0, and sD[ sN (Fig. 1-14).
Cur B Neither Cur A nor Cur C R1.
sStage IVa, sStage IVb or sD^sN, but R0 was
achieved with resection of a T4b tumor or complete
removal of metastatic tumor (M1) or lymph nodes.
Cur C Residual tumor.
R2, i.e., M1 evident residual tumor in distant
organ(s) (M1), lymph nodes, or surgical
margin(s) (PM1, DM1, RM1).
4. Pathological findings
4.1. Handling of the surgically resected specimens
(Fig. 1-15)
Before cutting the resected esophagus, the formalin-fixed
specimen should be treated with iodine solution to confirm
the unstained area. Rinsing the sample with tap water for at
least 1 h can result in a good staining condition. To
increase the contrast between stained and unstained areas,
the sample should be treated with a relatively low con-
centration (0.1–0.5%) of iodine solution for a long time.
The resected specimen should be cut parallel along the
long axis of the esophagus. Whole step sections are made
in superficial type cancer. One representative section of an
advanced tumor at the site of deepest invasion, parallel or
perpendicular to the esophagus should be blocked and used
for microscopic examination. Schemas or photographs of
the sites of cut sections should be preserved.
Table 1-8 Surgical curativity
Stage N and D PM, DM, RM R
Cur A Stage 0, I, II, III D[N PM0, DM0, RM0 R0
Cur B Neither Cur A nor Cur C
Cur C Residual tumor assessed by surgical (macroscopic) findings,
R2
No
Pre- and intraoperative gross findings
Residual distant metastasis?
Residual loco-regional tumor?
Histopathological examination of the resection 
specimens, primary and if submitted, resected 
distant metastasis:
Resection lines and planes contain tumor?
R2: Macroscopic residual tumor
R1: Microscopic residual tumor
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4.2. Description of pathological findings
The p (pathology) mark is prefixed to the pathological
findings except for vascular invasion as follows.
e.g.: p0-Is, pType 2, pT2, pStagedII.
4.2.1. Histological classification
4.2.1.1. Benign epithelial neoplasmsNote 1
1. Squamous cell papilloma
2. Adenoma
3. Others
4.2.1.2. Intraepithelial neoplasiasNote 2–7
1. Squamous intraepithelial neoplasia
4.2.1.3. Malignant epithelial neoplasms












7. Adenoid cystic carcinoma
8. Neuroendocrine cell tumorNote 8





1. Smooth muscle tumor
2. Gastrointestinal stromal tumor (GIST)
3. Neurogenic tumor
Schwannoma, neurofibroma, granular cell tumor.
4. Others
Hemangioma, lymphangioma, lipoma, etc.
4.2.1.5. Lymphoid tumors
The definition is according to the WHO classification.
[Reference]
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues, fourth edition. IARC,
Lyon, 2008.









Note 1: Squamous papilloma is not a true neoplasia, but
reactive hyperplasia.
Note 2: Adenocarcinoma and a tumor-like lesion arising
from Barrett mucosa are excluded. The classification of
adenocarcinoma in Barrett esophagus is the same as that
in the Japanese Classification of Gastric Carcinoma.
Note 3: According to the WHO classification, high-grade
intraepithelial neoplasia cannot be diagnosed as carci-
noma because of the absence of invasion. In the 11th
edition, however, intraepithelial squamous cell
Fig. 1-15 How to cut surgically resected specimens
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carcinoma (pT1a-EP carcinoma) or squamous cell
carcinoma in situ can be diagnosed when cellular and
structural atypia are sufficient to suggest malignancy.
The 10th edition mentioned that low-grade intraepithe-
lial neoplasia might contain basal-type squamous cell
carcinoma. When such lesions are distributed in the
lower half of the epithelium and are sufficiently atypical
to suggest malignancy, the lesion can be diagnosed as
squamous cell carcinoma according to the classification
of the 11th edition.
Note 4: Most ‘‘squamous intraepithelial neoplasias’’
according to the definition of the 11th edition are
endoscopically or macroscopically recognized as a
‘‘small unstained or tan-stained area’’. The lesion may
be solitary or multiple.
Note 5: According to the definition of the 11th edition,
intraepithelial neoplastic lesion without atypia sufficient
to suggest malignancy is termed as squamous intraep-
ithelial neoplasia. Thus, intraepithelial neoplasia does
not include squamous cell carcinoma in situ. Please be
careful to note the differences in the definitions of
intraepithelial neoplasia between the 10th and 11th
editions. A two-tier subclassification of intraepithelial
neoplasia (low grade and high grade) is not used in the
11th edition. In making a diagnosis of intraepithelial
neoplasia based on a biopsy specimen, the inclusion of
one of the following comments is recommended:
‘‘follow-up is needed’’, ‘‘re-biopsy after a short time
period should be recommended’’, or ‘‘immediate re-
biopsy is strongly recommended because of suspicious
carcinoma’’.
Note 6: When the determination of a biopsy specimen as
‘‘neoplastic’’ or ‘‘reactive’’ is difficult, the specimen
should not be diagnosed as ‘‘intraepithelial neoplasia’’,
but rather as ‘‘atypical epithelium’’ or ‘‘atypical epithe-
lium, indefinite for neoplasia’’. For clinicians, the
inclusion of instructions such as the need for a re-biopsy
is recommended.
Note 7: Squamous cell carcinoma, which is limited to
within the epithelial layer without invasion, is different
from squamous intraepithelial neoplasia. Squamous cell
carcinoma in situ is equal to squamous cell carcinoma
with a depth of pT1a-EP.
Note 8: Neuroendocrine tumor and neuroendocrine
carcinoma are formally classified as carcinoid tumor
and endocrine cell carcinoma, respectively. These terms
have been adopted according to the WHO classification.
In Japan, however, ‘‘endocrine cell carcinoma’’ is
considered to be the correct term, since endocrine cells
in the gastrointestinal tract originate from gastrointesti-
nal stem cells.
4.2.2. Depth of tumor invasion (pT)Note 1–7
Note 1: Intraductal spreading of cancer is categorized as
pT1a-EP, and if the tumor invades beyond the duct of
the esophageal gland, the depth of tumor invasion is
defined as the layer presenting extraductal invasion of
cancer.
Note 2: The vertical depth of submucosal invasion is
measured from the muscularis mucosae, and the depth is
recorded in parentheses.
e.g.: pT1b-SM2 (400 lm).
Note 3: The depth of tumor invasion is defined histolog-
ically as the point of deepest direct invasion by the primary
tumor. Vascular invasion within the confines of the
primary tumor should be regarded as the depth of direct
tumor invasion. However, when vascular invasion is
found outside the confines of the primary tumor, the depth
of such invasion should be specified in parentheses after
the depth of direct invasion. For example, when a primary
tumor has invaded into the submucosa (pT1b) but
lymphatic invasion is found in the muscularis propria
outside themain tumor, this is designated as pT1b (ly-T2).
Note 4: Cancer that has macroscopically invaded
adjacent organ(s) (sT4) and histologically diagnosed
malignant tissue recognized on the surgical radial
margin (pRM1) are categorized as pT4.
Note 5: Direct invasion of tumor from lymph node
metastasis to the adjacent organ(s) is categorized as pT4.
e.g.: Direct invasion from No.108 lymph node metastasis
to the lung: pN1 (108-lung) T4a
Note 6: In determining the depth of invasion of an
advanced cancer after preoperative treatment, both the
depth of invasion by residual tumor and the estimated
depth of tumor invasion prior to treatment should be
considered. The type of adjuvant therapy (RT-, CT-,
CRT-, EMR-), depth of invasion by the residual tumor,
and estimated depth of tumor invasion prior to treatment
should be specified in the given order, with the last item
in parentheses. e.g.: RT-pT1b (T4).
Note 7: If no residual tumor is found in an entire
specimen after preoperative treatment, the designation
should be pT0, and its stage is recognized as the same as
T1a.
e.g.: CRT-pT0 (T3), N0, M0, CRT-pStage 0.
4.2.3. Infiltrative growth pattern (INF)
The growth and infiltrative pattern of tumor can be clas-
sified into one of the following three types, with regard to
the predominant pattern observed at tumor margins.















Infiltrative growth of tumor nests with
an ill-defined border from surrounding
tissue.
4.2.4. Vascular invasion (ly/v)Note 1
Note 1: Indefinite for determination of lymphatic or
venous invasion is described as ly/v.





Note 1: Examination using immunohistochemical stain-
ing with an anti-D2-40 antibody should be described.
e.g.: ly1 (D2-40).
Note 2: Carcinomatous lymphangiosis in distant
organ(s) is categorized as M1.
Note 3: A tumor mass found in the thoracic duct is
described as positive lymphatic invasion.





Note 1: Examination by elastic fiber staining methods
should be described.
e.g.: v1 (Elastica van Gieson), v2 (Victoria blue).
4.2.5. Intramural metastasis (pIM)
4.2.6. Distance from Surgical margin
4.2.6.1. Proximal and distal margin (pPM, pDM)Note
Note: The distance from surgical margin to tumor edge
in pPM0 or pDM0 is measured in histological specimens
(mm).
4.2.6.2. Radial margin (pRM)
4.2.7. Multiple primary cancers
Present (number of lesions).
Absent.
Note: A lesion with a histological type different from
that of the main tumor or an isolated lesion with an
intraepithelial component is recognized as another
primary cancer, and the patient is classified as having
multiple primary cancers.
4.2.8. Others
1. Metastatic or invasive cancer from other organs.
2. Co-existing tumor.
Leiomyoma, etc.
3. Other non-neoplastic lesions.
Barrett esophagus, Achalasia, etc.
4.2.9. Pathological criteria for the effects of radiation and/
or chemotherapy (Fig. 1-16)
In cases of preoperative radiation and/or chemotherapy,
the radiation dose and method of administration, type
and dose of chemotherapy, and time interval between
preoperative therapy and surgical resection of the tumor
are described. In cases of preoperative treatment, all the
specimens in which the primary tumor is macroscopi-
cally possibly present should be examined
histologically.
Grade 0: ineffective
No recognizable cytological or histological therapeu-
tic effect.
Grade 1: slightly effective
Apparently viable cancer cells (including cells having
eosinophilic cytoplasm with vacuolation and swollen
nuclei) account for 1/3 or more of tumor tissue, but
there is some evidence of degeneration of cancer
tissue or cells.
Grade 1a: Viable cancer cells accounting for 2/3
or more tumor tissue.
Grade 1b: Viable cancer cells accounting for 1/3
or more, but less than 2/3, of tumor tissue.
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Grade 2: Moderately effective
Viable cancer cells account for less than 1/3 of tumor
tissue, while other cancer cells are severely degener-
ated or necrotic.
Grade 3: Markedly effective
No viable cancer cells are evident.
Note: Definite re-proliferation of tumor cells in treated
cancer lesions, after preoperative treatment, should be
recorded as ‘‘re-proliferation (?)’’.
4.3. Lymph node metastasis (pN)
Note 1: Lymph nodes should be sectioned through the
hilum.
Note 2: The number of dissected lymph nodes and
metastatic lymph nodes should be recorded.
Note 3: The metastatic ratio (the number of metastatic
lymph nodes/the number of dissected lymph nodes) is
described for each lymph node station. The total
metastatic ratio is also described in parentheses.
e.g.: No.104R (0/10), No.104 L (1/13), No.106recR (1/
3), No.106recL (0/4).
Note 4: Metastasis to soft tissue without a lymph node
structure is described as extra-lymph node metastasis,
and the locations and number of metastases are recorded.
e.g.: lymph node metastasis, 1/25; extra-lymph node
metastasis, 2/2.
Note 5: Extranodal invasion including direct invasion
and lymphatic invasion is described.
Note 6: A lymph node with no viable cancer cells after
preoperative treatment is diagnosed as negative for
metastasis (pN0).
[Reference]
Japanese Gastric Cancer Association: Japanese Classification of Gastric
Carcinoma (in Japanese). 13th ed. Kanehara Shuppan, Tokyo, 1999; 27.
4.4. Distant organ metastasis (pM) (cf. 3.5 Distant organ
metastasis (M))
4.5. Residual tumor (pR) (cf. 3.6 Residual tumor (R))
4.6. Curativity (pCur) (cf. Curativity (Cur))
5. Endoscopic treatment
5.1. Handling of specimens resected endoscopicallyNote
Extending fixation of the resected specimen: A specimen is
extended and fixed immediately after resection on a cork
board or polystyrene foam and is fixed in formalin solution
of sufficient volume for at least half a day.
Note: As for the extended fixation of the resected
specimen, it should be done by the doctor or co-worker
who carried out endoscopic treatment. Especially in
piecemeal resection, fixation of the specimen should be
performed by the doctor(s) aware of the actual figure of
the tumor in vivo to enable more exact restructuring.
5.2. Description of macroscopic findings and endoscopic
findings
An e-mark is prefixed to macroscopic findings and endo-
scopic findings.
5.2.1 Number of tumors and number of resected specimens
Number of lesions
Number of specimens resected from each tumor (number
of specimens):
1. en bloc resection, 2. piecemeal resection.
5.2.2 Size of resected specimen and size of tumor lesion
(for each lesion)
The size is described by the greatest longitudinal dimen-
sion in millimeters multiplied by the greatest transverse
dimension in millimeters: a 9 b (mm).
Fig. 1-16 Histological efficacy of chemotherapy and/or radiotherapy
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5.2.3 Tumor types
The tumor types are classified into Type 0-I, Type 0-IIa,
Type 0-IIb, Type 0-IIc, Type 0-III, combined type, and
others.
5.2.4 Macroscopic findings
5.2.4.1. Horizontal margin (eHM)
eHMX Whether residual tumor is present on the
horizontal margin cannot be assessed.
eHM0 Non-cancerous squamous epithelium and lamina
propria mucosae have been confirmed on all
horizontal resection margins.
eHM1 The tumor is exposed on one of its horizontal
resection margins.
5.2.4.2. Vertical margin (eVM)
eVMX Whether residual tumor is present on the vertical
margin cannot be assessed.
eVM0 The tumor is not exposed on any of its vertical
margins.
eVM1 The tumor is exposed on one of its vertical
margins.
5.2.5. Clinical assessment of residual tumorNote 1, 2
eRX
(non-assessable)
Whether residual tumor is present





epithelium and lamina propria





Presence of an iodine-unstained




Presence of residual tumor.
Note 1: The clinical assessment of the residual tumor,
referring to the iodine staining of the resected specimen,
should be performed immediately after the endoscopic
resection. In cases with a piecemeal resection, iodine
staining of the ulcer margin after resection should be
referenced.
Note 2: This assessment method should be applied to
squamous cell carcinoma.
5.3. Preparation for pathological examination (Fig. 1-17)
Before cutting, formalin-fixed specimen should be stained
with iodine solution to confirm unstained area.Note Cutting
lines are decided as crossing lines at right angles to the
tangent line at the resection margin closest to the tumor,
and a whole resected specimen is cut in slice each 2–3 mm
thick.
Note: Rinsing the sample with tap water for at least
30 min can result in a good staining condition. To make
a clearer contrast between stained and unstained areas,
the sample should be treated with relatively low
concentration (0.1–0.5%) of iodine solution for a little
bit longer time.
5.4. Description of pathological findings
The pathological diagnosis of an endoscopically resected
specimen is summarized by the histological type, depth of
tumor invasion, assessment of resection margin (horizontal
and vertical), and vascular invasion.
5.4.1. Pathological diagnosis
The diagnosis is based on the histological classification
(4.2.1). Although most esophageal tumors are squamous
cell carcinoma, the evaluation of histological differentia-
tion is omitted for intraepithelial carcinoma.
5.4.2. Depth of tumor invasion (pT)
A mucosal cancer is categorized in three depths of pT1a-
EP, pT1a-LPM and pT1a-MM. In a submucosal cancer, the
Fig. 1-17 How to cut endoscopically resected specimens
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distance from the lamina muscularis mucosae is described
because the entire submucosal layer cannot be examined in
an endoscopically resected specimen. A submucosal cancer
is sub-classified as pT1b-SM1 (submucosal tumor invasion
limited to within 200 lm) and pT1b-SM2 (invasion to
more than 200 lm).
e.g.: pT1b-SM2, 300 lm.
5.4.3. Resection marginNote 1, 2
5.4.3.1. Horizontal margin (pHM)
pHMX It cannot be assessed whether there is residual
tumor on the horizontal margin or not.
pHM0 Non-cancerous squamous epithelium and lamina
propria mucosae are confirmed on all horizontal
resection margins.
pHM1 The tumor is exposed on any horizontal resection
margin.
5.4.3.2. Vertical margin (pVM)
pVMX It cannot be assessed whether there is residual
tumor on the vertical margin or not.
pVM0 No tumor is exposed on any vertical margin.
pVM1 The tumor is exposed on any vertical margin.
Note 1: When no tumor is recognized in any resection
margin, it is defined as a complete resection (pR0), and
when a tumor is recognized in any resection margin, it is
defined as an incomplete resection (pR1).
Note 2: When vascular invasion is present in the
resection margin, it is defined as a positive resection
margin (pHM1, pVM1).
5.4.3.3. Non-assessable resection margin (pRX)
1. Because of crushing injury or the burn effect in the
specimen during endoscopic resection, non-cancerous tis-
sue in the resection margin cannot be confirmed.
2. Reconstruction after piecemeal resection is impossible.Note
3. Suspected residual tumor in the basal layer because of
non-continuous tumor extension.
4. Possible residual tumor in the vertical margin because of
intra-ductal spread.
5. Indeterminable residual tumor because of other reasons.
Note: In piecemeal resection pR0 is confirmed only
when restructuring is possible and only non-cancerous
tissue is recognized at the resection margins of the
restructured specimen.
5.4.4. Infiltrative growth pattern (INF)
INFa (expansive
type)
Expansive growth of tumor nests with a










Infiltrative growth of tumor nests with
an ill-defined border from the
surrounding tissue.
5.4.5. Vascular invasion (ly/v)Note
It is not necessary to evaluate the degree of vascular involve-
ment: only its presence or absence should be described.
5.4.5.1. Lymphatic invasion (ly)
ly (-) No lymphatic invasion.
ly (?) Lymphatic invasion
5.4.5.2. Venous invasion (v)
v (-) No venous invasion
v (?) Venous invasion
Note: A special staining method for elastic fibers of the
vascular wall, such as Elastica van Gieson (EVG) or
Victoria blue (VB) staining, is needed to determine venous
invasion. Immunostaining with an anti-D2-40 antibody is
useful to confirm lymphatic invasion. When differentiat-
ing between lymphatic and venous invasion is difficult, the
case should be described as ly/v. When lymphatic and/or
venous invasion is prominent, this evaluation should be
included in addition to ly (?) or v (?).
5.4.6. Report of pathological findings
All the above-mentioned factors should be described, and
the attachment of a figure showing the general view of the
resected specimen with the regional depths of tumor
invasion and vascular invasion is recommended. It is better
to attach a schematic figure showing pathological findings
on the cut surface if necessary.
5.5 Residual tumor (pR)Note 1,2
pRX The existence of residual tumor at the resection
margin cannot be assessed pathologically.
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pR0 No cancer tissue is pathologically present at any
margin of the resected specimen.
pR1 Cancer tissue is pathologically present at the
margin of the resected specimen.
pR2 A cancer lesion is present.
Note 1: For a piecemeal resection, the presence of residual
tumor is evaluated after rebuilding the specimen.
Note 2: When multiple lesions are resected, each lesion
is evaluated individually.
5.6. Curativity (pCur)
When endoscopic resection (EMR: endoscopic mucosal
resection, or ESD: endoscopic submucosal dissection) is
performed for superficial esophageal cancer that does not
exhibit clinical metastasis, a comprehensive evaluation can
be established, based on the pathological findings of depth of
invasion, residual tumor, and vascular invasion (Table 1–9).
Curativity A
(pCur A)
pT1a-EP or pT1a-LPM with pR0.
Curativity B
(pCur B)
pT1a-EP or pT1a-LPM with pRX.




pT1b-SM2, positive micro vascular
permeation despite depth of invasion,
pR1 or pR2.
6. Barrett esophagus and adenocarcinoma
in Barrett esophagus
6.1. Definition and description methods for Barrett mucosa,
Barrett esophagus and Adenocarcinoma in Barrett
esophagus
6.1.1. Definition of the esophagogastric junction (EGJ)
The EGJ should be defined systematically in accordance
with the criteria listed below. Among these criteria,
endoscopic findings should be given priority over findings
obtained using other diagnostic modalities.
1. Endoscopic findings
Lower margin of palisading small vessels
If the palisading small vessels are unclear, the oral
margin of the longitudinal folds of the greater
curvature of the stomach is defined as the EGJ.
2. Upper gastrointestinal series (UGI)
Narrowest locus of the lower esophagus
In the presence of a sliding hiatal hernia, the upper
end of the longitudinal folds is defined as the EGJ.
In the presence of Barrett esophagus, the upper end
of the longitudinal folds is defined as the EGJ.
3. Pathological study
Macroscopic definition: The EGJ should be defined
macroscopically as the point at which the luminal caliber
changes in the area where the tubular esophagus is
connected to the vestibule lumen of the stomach.
Microscopic definition: For a mucosal layer with intact
structures, the EGJ should be defined as follows:
1. Non-Barrett esophagus: The EGJ is defined as the
squamocolumnar junction.
2. Barrett esophagus: Histological structures such as
proper esophageal glands and their ducts, a
double-layer muscularis mucosae, or palisading
small vessels should be included in the micro-
scopic definition of the EGJ.
For a non-intact mucosal layer, the EGJ should be
defined based on the macroscopic findings of the sur-
gical specimen, and the EGJ should be presumed based
on the presence of histological structures associated
with the esophagus or stomach.
6.1.2. Barrett mucosa
Columnar epithelium continuous from the stomach with or
without intestinal metaplasia
6.1.3. Barrett esophagus
An esophagus containing Barrett mucosa should be des-
ignated as Barrett esophagus.Note 1
At least one of the following conditions must be satisfied.
1. Presence of esophageal gland ducts in the mucosal
layer or proper esophageal glands in the submucosal
layer within the area of columnar epithelium.
2. Presence of squamous islands in the columnar
epithelium.
Table 1-9 Curativity of the endoscopic resection
Depth of tumor invasion (T) Residual tumor
(R)
Others
pR0 pRX pR1, pR2 and/or
v ? , ly?
pT1a-EP A B C
pT1a-LPM A B C
pT1a-MM B B C
pT1b-SM1 B B C
pT1b-SM2 C C C
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3. Presence of a double-layer muscularis mucosaeNotes 2,3
Note 1: The presence of circular Barrett mucosa
extending longitudinally for 3 cm or more is called long
segment Barrett esophagus (LSBE) (Fig. 1-18). On the
other hand, the presence of circular Barrett mucosa less
than 3 cm in length or the presence of non-circular
Barrett mucosa is designated as short segment Barrett
esophagus (SSBE) (Fig. 1-19).
Note 2: New muscularis mucosae can sometimes be found
immediately under the columnar epithelium. In the Japanese
Classification, the primary muscularis mucosae is called
deep muscularis mucosae (DMM), and the new muscularis
mucosae is called superficial muscularis mucosae (SMM).
The identification of SMM and DMM is occasionally
difficult because of the fusion of both layers, the thickness of
the layer, or the presence of irregularities.
Note 3: Barrett esophagus can also be defined as the
presence of columnar epithelium containing small pal-
isading vessels with diameters of greater than 100 lm
within the lamina propria mucosae.
6.1.4. Adenocarcinoma in Barrett esophagus
Adenocarcinoma arising in Barrett mucosaNote 1
Note 1: The origin of adenocarcinoma in areas of Barrett
esophagus is not the same as that of gastric adenocar-
cinoma, which is derived from gastric mucosa adjacent
to the EGJ. Gastric cancer is described according to the
Japanese Classification of Gastric Cancer, and esopha-
geal adenocarcinoma is described according to the
Japanese Classification of Esophageal Cancer. However,
the histological classifications of both adenocarcinomas
are described according to the Japanese Classification of
Gastric Cancer.
Circular Barrett mucosa extending longitudinally for 3 cm
or more is called long segment Barrett esophagus (LSBE).
6.2. Tumor location
Same as that for esophageal cancer.
Note: In cases with a hiatus hernia, the tumor location
should be determined using barium contrast radiography.
6.3. Description of tumors
Adenocarcinoma in Barrett esophagus is described
according to the Japanese Classification for Esophageal




6.3.1.3. Macroscopic tumor types
6.3.1.4. Depth of tumor invasion (T)
TX Depth of tumor invasion cannot be assessed.
T0 No evidence of primary tumor.
T1a Tumor has invaded the mucosa.
T1a-SMM Tumor has invaded the superficial muscularis
mucosae (SMM).
T1a-LPM Tumor has invaded the lamina propria
mucosae.
T1a-DMM Tumor has invaded the deep muscularis
mucosae (DMM).
T1b Tumor has invaded the submucosa (SM).
SM1 Tumor has invaded the upper third of the
submucosa.
Fig. 1-19 Short segment Barrett esophagus (SSBE). Circular Barrett
mucosa extending for less than 3 cm in length or non-circular Barrett
mucosa is designated as short segment Barrett esophagus (SSBE).
a Circular SSBE. b Non-circular SSBE
Fig. 1-18 Long segment Barrett’s esophagus (LSBE)
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SM2 Tumor has invaded the middle third of the
submucosa.
SM3 Tumor has invaded the lower third of the
submucosa.
T2 Tumor has invaded the muscular propria.
T3 Tumor has invaded the adventitia.
T4 Tumor has invaded adjacent structure(s).
6.3.2. Intramural metastasis (IM)
Same as that for esophageal cancer.
6.3.3. Lymph node metastasis (N)Note
Note: In cases with a hiatal hernia, the field of lymph
node dissection should be designated according to the
tumor location as defined using Barium contrast
radiography.
6.3.4. Distant organ metastasis (M)
Same as that for esophageal cancer.
6.4. Stage
Same as that for esophageal cancer.
7. Treatment
7.1. Endoscopic treatment
7.1.1. Endoscopic resection: ER
7.1.1.1. Endoscopic mucosal resection: EMR
7.1.1.2. Endoscopic submucosal dissection: ESD
Note: The following items should be described.
Method of resection: (1) en bloc resection, (2) piecemeal
resection.
Residual tumor: eRX, eR0, eR1, eR2.
Complications: (1) perforation, (2) bleeding requiring
treatment, (3) stenosis, (4) others (in-
cluding mediastinal emphysema).
Combined therapy: (1) none, (2) APC, (3) laser, (4) PDT,
(5) MCT, (6) others.
7.1.2. Other Endoscopic treatments
7.1.2.1. Argon plasma coagulation: APC
7.1.2.2. Laser therapy: laser
7.1.2.3. Photodynamic therapy: PDT
7.1.2.4. Microwave coagulation therapy: MCT
7.1.2.5. Others
Note: Any other therapy performed should be described.
7.2. Surgical treatments




7.2.1.2. Surgery with multi-modality treatments
Planned surgery: planned surgery after neoadjuvant
chemotherapy, radiotherapy, or both.
Salvage surgery: surgery for cases with residual tumor or
cases with recurrent tumor after definitive chemoradio-
therapy with more than 50 Gy radiation.
The surgical methods, such as esophagectomy, lym-
phadenectomy, endoscopic resection, and so on, should be
described.















Note: When several approaches are adopted, only the
main approach should be described.
7.2.1.4. Extent of esophageal resection
Total esophagectomy: the cervical, thoracic and abdominal
esophagus is resected, regardless of whether laryngectomy
is done or not.
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Subtotal esophagectomy: almost all the thoracic esophagus
is resected
Middle and lower esophagectomy: the middle and lower
esophagus (including abdominal esophagus) is resected
Note 1
Lower esophagectomy: the lower esophagus (including
abdominal esophagus) is resected
Partial esophagectomy: resection of full-thickness partial
esophagusNote 2
Mucosal resection: resection of mucosal and submucosal
layers
Others
Note 1: Lower esophagectomy includes resection of the
lower esophagus and cardia.
Note 2: In partial esophagectomy, the location of the
esophagus resected should be described.
7.2.1.5. Combined resection
The organ(s) resected together because of cancer invasion
should be described.







7.2.1.6.2. Sites of anastomosis
Neck
Antethoracic (subcutaneous)
Thoracic cavity (proximal, distal)
Lower mediastinum
Note: The border between the proximal and the distal
site of anastomosis is the upper level of the aortic arch.























Note 1: Isoperistaltic or antiperistaltic should be
described.
Note 2: For reconstruction with left colon, the transverse
colon with left colic artery is used.
Note 3: For reconstruction with right colon, the ascend-
ing colon with the middle colic artery is used.
Note 4: The name of the skin flap or muscle flap that is
used should be described.













7.2.2.3. Exploratory thoracotomy, exploratory laparotomy
7.2.2.4. Others
Lymph node dissection without esophagectomy




(a) Therapy before stenting
No
Yes (chemotherapy, radiotherapy, chemoradio-
therapy, others)
(b) Therapy after stenting
No





(d) Type of stent
Covered or non-covered





Yes (bleeding requiring treatment, dyspnea, pain,
others)
(f) Evaluation of stent
Status of eating before stenting
Status of eating at discharge
(g) Complications after stenting
No
Yes (bleeding requiring treatment, perforation,
pain, regurgitation of gastric contents, dyspnea,





7.4. Common issues for radiotherapy and chemotherapy
7.4.1. Disease status
Untreated
Macroscopic residual after surgery
Microscopically residual after surgery
No obvious residual disease after surgery
Loco-regional recurrence after surgery
Distant metastasis after surgery
Other postoperative recurrence
Residual disease after EMR/ESD
No obvious residual disease after EMR/ESD
After stenting
After intraoperative radiation therapy for macroscopic
disease
After intraoperative radiation therapy for no obvious
macroscopic disease













7.5.1. Clinical target volume (CTV)
Primary lesion
Entire esophagus
Resected lymph node area for prevention (supra-clavicular,
mediastinal, abdominal)
Distant organ metastasis
7.5.2. Methods of radiotherapy
External beam radiation therapy
External beam radiation therapy ? intra-cavitary radiation
therapy
Intra-cavitary radiation therapy alone































Low dose rate (226Ra)













7.5.6. Reasons for treatment cessation
Completion of the planned treatment
Disease progression
Adverse events
Patient’s refusal (related to adverse events)
Patient’s refusal (not related to adverse events)
7.6. Chemotherapy (CT)
7.6.1. Agents

















Upper limit in number of courses.
7.6.6. Duration of administration
Initial date of administration
Last date of administration
Total number of courses
7.6.7. Total administration dose
Total administration dose of each agent should be calcu-
lated as per body surface area or per body.
7.6.8. Reasons for treatment cessation
Completion of the planned treatment
Disease progression
Adverse events
Patient’s refusal (related to adverse events)
Patient’s refusal (not related to adverse events)
Others
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7.6.9. Adverse events
Recorded in accordance with the ‘‘Common Terminology
Criteria for Adverse Events ver. 4, (Japanese version)
JCOG/JSCO edition’’.
7.7. Multi-modality treatment
7.7.1 Combination of endoscopic treatment and surgery,
radiotherapy, chemoradiotherapy or chemotherapy
Classification Preoperative, intraoperative, or
postoperative.
Description Planned treatment or salvage treatment
Surgery Evaluation of residual tumor (pR)
(If a residual tumor is present, describe the
tumor location, depth of tumor invasion,
tumor margin, presence of vascular
invasion, presence of lymph node
metastasis, etc.)
Multiple tumors: yes or no
(If multiple tumors are present, describe
the tumor location and the number of
lesions.)
Note: Evaluate residual tumors of pri-
mary and metastatic lesions.
Radiotherapy: radiation field, total dose
Chemotherapy: regimen
7.7.2 Chemoradiotherapy (CRT)
Classification according to timing: concurrent or sequential
Classification according to intent: definitive, neoadjuvant,
or after surgery (adjuvant, additive)
Note: R0 resection should be recorded as adjuvant. R2
should be recorded as additive.
7.8. Hyperthermia (HT)
7.9. Immunotherapy (IT)
8. Results of treatment
The following matters are recorded to allow precise sta-
tistical analysis for a comprehensive registry of esophageal
cancer.
8.1. Total number of patients
Total number of outpatients
Total number of admitted patients
Total number of patients admitted for various treatments
8.2. Multiple primary cancers
Primary lesion of another cancer, diagnosis (clinical and
pathological), synchronous or metachronous, and treatment









8.4. Total number of patients treated, and number and rate
of patients treated with each procedure
8.4.1. Patients operated
The total number of patients admitted, the number of
patients who underwent resection, the numbers of patients
with curative and non-curative resections, and the resection
rate should be recorded.
Resection rate = patients who underwent resection/pa-
tients admittedNote 1
Total number and ratio of patients with or without curative
resectionNotes 2, 3
Note 1: Patients who have undergone an esophagectomy
for the first time are evaluated.
Note 2: Curative operation is defined as Curativity A or
B resection.
Note 3: Non-curative operation is defined as Curativity
C resection.
8.4.2. Patients with Endoscopic treatment
Record the number of patients who underwent endoscopic
treatment, and the total number and ratio of patients with or
without curative resection.
Cases of treatment completed only by endoscopic treat-
ment are recorded separately from operated cases as
endoscopically treated cases.
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One-piece resection rate = (number of patients who
underwent one-piece resection/total number of patients
who underwent endoscopic resection) 9 100Note
Curativity rate = (number of patients who underwent
curative endoscopic resection/total number of patients who
underwent endoscopic resection) 9 100
Note: The number of patients who underwent endo-
scopic resection indicates those who underwent endo-
scopic mucosal dissection and endoscopic submucosal
dissection. It does not include the number of patients
treated by laser therapy or photodynamic therapy.
8.4.3. Patients with chemotherapy and/or radiotherapy
Total numbers and rates according to response evaluation
criteria after treatment.
8.5. Operative mortalityNote
Operative mortality = (operative deaths/patients oper-
ated) 9 100
Mortality after esophagectomy = (deaths after esophagec-
tomy/patients who underwent esophagectomy) 9 100
Note: Operative death means death within 30 days after
operation in or out of hospital.
8.6. Hospital mortalityNotes 1, 2
Hospital mortality = (hospital deaths/patients operated) 9
100
Hospital mortality after esophagectomy = (hospital deaths
after esophagectomy/patients who underwent esophagec-
tomy) 9 100
Note: Hospital death is defined as death during the same
hospitalization, regardless of department at time of
death.
8.7. Long-term outcome
The following items should be recorded for survival
analysis.
8.7.1. Alive or dead
Alive: The date of the most recent follow-up
Death: The date of death
Unknown: The date of the most recent follow-up
Cause of death
Treatment-related death: death because of surgical
treatment, chemotherapy, radiotherapy, or other
therapies
Death because of esophageal cancer
Death because of another cancer: primary cancer-
related deaths should be recorded.
Death because of another disease: the name(s) of the
disease(s) should be recorded.
Death because of accident: suicide should be included.
Death because of unknown cause(s): this category





Pattern and site of recurrence: Each recurrence should be
recorded chronologically
Local recurrence
Primary lesion (esophagus)Note 1
Recurrence in the mediastinum adjacent to the
primary lesion
Recurrence at the anastomotic site or in the esopha-
geal stump
Recurrence in the regional lymph nodes




Hematogenous recurrence (distant organ(s))
Disseminated recurrence (pleura, peritoneum,
pericardium)
Unknown
Note 1: Recurrence at the same place as the primary
lesion in the esophagus can occur after esophagus-
preserving treatment including endoscopic mucosal
resection, chemotherapy and radiotherapy.
Note 2: Recurrent organ(s) are indicated by the abbre-
viations of the TNM classification.
Liver: HEP, Lung: PUL, Peritoneum: PER, Lymph
node: LYM, Bone: OSS.
Brain: BRA, Kidney: REN, Adrenal gland: ADR, Skin:
SKI, Others: OTH.
8.8. Long-term outcomes and prognosis, especially sur-
vival rate
8.8.1. Analysis of survival rates
Target (operation, endoscopic treatment, curativity and so on)
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The calculation method of survival rates
Crude survival rate: direct method, cumulative method
(Life-table method, Kaplan–Meier method)
Relative survival rate
Censored cases: overall survival rate, cause-specific sur-
vival rate
Statistical analysis of survival rate
Rate of cases lost to follow-up
8.8.2. Period and rate of esophageal preservation
This is the period during which the esophagus is preserved
in patients with esophageal cancer who underwent non-
esophagectomy treatment such as endoscopic mucosal
resection, endoscopic submucosal dissection, chemother-
apy and/or radiotherapy. The rate of those patients per all
patients who underwent treatment for esophageal cancer is
described.
[Reference]
Murakami M, Kuroda Y, Matsumoto S, et al. Treatment results of eso-
phageal carcinoma of clinical T3, T4 M0: histological comparison
between neoadjuvant chemoradiotherapy followed by surgery or definitive
radiotherapy and conventional surgery. Oncol Rep 2000; 7: 571–578.
8.9. Terminology related to survival period
8.9.1. Survival time
Time until death from the time of a certain event
8.9.2. Overall survival (OS)
Time until death regardless of cause from the initial date.
In observation studies, the day starting treatment, or the
day confirming diagnosis is used as the initial date. In
clinical trials, the ‘‘registration date’’ (the allocation day in
the case of a randomized controlled trial) is used.
8.9.3. Median survival time (MST)
Period from the initial date to the first date of the survival
rate being less than 50% in the survival curve calculated by
the Kaplan–Meier method. The initial date is the same as
described in 8.9.2.
8.9.4. Survival rate
The rate of survivors at a given time
8.9.5. Progression-free survival (PFS), time to progression
(TTP)
It is the shortest period among periods from the initial date
to progression or recurrence, or death. Death from any
cause is regarded as an event, in PFS. Death is only
regarded as an event if it is caused by esophageal cancer, in
TTP.
8.9.6. Relapse-free survival, recurrence-free survival
(RFS)
This is the period between the initial date to recurrence or
death.
The day when the disease-free state was achieved such as
an operation day, is used as the initial date.
8.9.7. Disease-free survival (DFS)
It is the shortest period among the periods from the initial
date to a recurrence, death, or diagnosis of a second pri-
mary cancer. The day when the disease-free state such as
an operation day was achieved, is used as the initial date.
8.9.8. Time to treatment failure (TTF)
This is the shortest period among the periods from the
initial date to treatment cessation, progression, and death.
8.9.9. Response duration
Period from the first day when the disease was assessed as
CR or PR until progression.
8.9.10. Complete response duration
Period from the first day when the disease was assessed as
CR until recurrence.
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